Novel CD123xCD3 bispecific IgM antibody shows strong efficacy in AML models
Dec. 12, 2023
High expression of CD123, the IL-3 receptor α chain (IL-3α), is observed on both leukemic blasts and leukemic stem cells, thus suggesting it can be considered an attractive therapeutic target in AML.